{"id":519933,"date":"2021-07-29T08:34:15","date_gmt":"2021-07-29T12:34:15","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity\/"},"modified":"2021-07-29T08:34:15","modified_gmt":"2021-07-29T12:34:15","slug":"fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fda-approves-expanded-botox-onabotulinumtoxina-label-to-include-eight-new-muscles-to-treat-adults-with-upper-limb-spasticity\/","title":{"rendered":"FDA Approves Expanded BOTOX\u00ae (onabotulinumtoxinA) Label to Include Eight New Muscles to Treat Adults with Upper Limb Spasticity"},"content":{"rendered":"
\n

— 6.7 million adults in the U.S. are living with spasticity across a variety of neurologic conditions<\/h2>\n

— BOTOX\u00ae has demonstrated efficacy and has an established safety profile with over 10 years of clinical use in adult upper limb spasticity<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NORTH CHICAGO, Ill.<\/span>, July 29, 2021<\/span> \/PRNewswire\/ — Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion of BOTOX\u00ae<\/sup> to include eight new muscles for the treatment of upper limb spasticity in adults.\u00a0The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis). The label now includes the use of ultrasound as a muscle localization technique in adult spasticity.<\/p>\n

“Today’s announcement is especially important because spasticity is a disabling neurological condition that can have a significant impact on a patient’s quality of life,” said Mitchell F. Brin<\/span>, M.D., Senior Vice President, Chief Scientific Officer, BOTOX\u00ae<\/sup>\u00a0& Neurotoxins, AbbVie.\u00a0“This label expansion not only adds to our rich history in neurotoxin science, but also reinforces the role of BOTOX\u00ae<\/sup> in upper limb spasticity treatment. BOTOX\u00ae<\/sup> provides an evidence-based dosing strategy to meet the clinical needs of providers and their patients.”<\/p>\n

Spasticity in adults is commonly caused by stroke, multiple sclerosis, spinal cord injury, cerebral palsy, and traumatic brain injury. Individuals with spasticity experience stiffness in the muscles of their upper and\/or lower limbs, and may have difficulty with voluntary control. Upper limb spasticity can manifest as a bent elbow, an arm pressed against the chest, or a curled-in hand with a clenched fist, significantly hindering the patient’s ability to perform everyday activities. This can result in difficulty with posture and positioning, and severely interfere with normal muscular movement and function. <\/p>\n

BOTOX\u00ae<\/sup> has been proven to significantly reduce muscle stiffness and is indicated for the treatment of spasticity in patients 2 years of age and older. This expanded BOTOX\u00ae<\/sup> dosing guidance provides physicians the ability to treat based on clinical assessment of a patient’s spasticity and anatomy while staying within the BOTOX\u00ae<\/sup> maximum cumulative dose of 400 Units in a 3-month period in adults. BOTOX\u00ae<\/sup> has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture. The safety profile of BOTOX\u00ae<\/sup> in adult upper limb spasticity remains the same, with the most common adverse reactions including nausea, fatigue, bronchitis, pain in extremity and muscular weakness.<\/p>\n

“BOTOX\u00ae<\/sup>\u00a0has demonstrated efficacy and safety for spasticity management at clinically proven doses,” said\u00a0Kimberly Heckert<\/span>, M.D., Director, Spasticity Management Fellowship, Thomas Jefferson University<\/span> of Philadelphia<\/span><\/span>. “This label expansion offers physicians and their patients living with spasticity another important tool as part of a comprehensive treatment plan for spasticity management.” <\/p>\n

\n BOTOX<\/b>
\n \u00ae<\/sup>
\n \u00a0Training and Support Programs<\/b>\n <\/p>\n

Allergan offers a variety of expert-based BOTOX\u00ae education and technical training programs to help physicians enhance their clinical skills and injection practices. These training programs focus on using guidance techniques, such as EMG, nerve stimulation, and now ultrasound, to help localize muscles for BOTOX\u00ae<\/sup> injection in adults with spasticity. In addition, the company is committed to providing resources and services, such as the BOTOX\u00ae<\/sup> Savings Program<\/a>, to help ensure BOTOX\u00ae<\/sup> is accessible and affordable to patients.<\/p>\n

\n About BOTOX\u00ae<\/sup><\/b>\n <\/p>\n

BOTOX\u00ae<\/sup>\u00a0was first approved by the FDA in 1989 for two rare eye muscle disorders \u2013 blepharospasm\u00a0and\u00a0strabismus\u00a0in\u00a0adults. Today, BOTOX\u00ae<\/sup>\u00a0is FDA-approved for 12 therapeutic indications, including chronic migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, adult and pediatric spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition. <\/p>\n

\n BOTOX\u00ae<\/sup><\/b>\u00a0(onabotulinumtoxinA) Important\u00a0Information<\/b><\/p>\n

\n Indications<\/b>\n <\/p>\n

BOTOX\u00ae<\/sup>\u00a0is a\u00a0prescription\u00a0medicine\u00a0that\u00a0is\u00a0injected\u00a0into\u00a0muscles and\u00a0used:<\/p>\n